Comparison of the Outcomes of Cytoreductive Surgery Versus Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: a Propensity Score Matching Analysis

Overview

Journal Surg Endosc

Publisher Springer

Specialties Gastroenterology
General Surgery
Radiology

Date 2020 Jul 8

PMID 32632486

Authors

Zhou Li

Juan de Dios Redondo Ntutumu

Shengyi Huang

Zhai Cai

Shuai Han

A I Balde

Zeyu Luo

Suzhen Fang

Affiliations

Soon will be listed here.

Abstract

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are effective treatment options for selected patients with peritoneal carcinomatosis (PC). We compared the short-term outcomes of surgery plus HIPEC and CRS alone for PC.

Methods: We retrospectively examined patients who underwent CRS-HIPEC for PC at a single center from 2014 to 2019 using the Chinese CRS-HIPEC patient database at our institution. Patients were divided into two groups: surgery plus HIPEC (450) and surgery alone (200). A 1:1 propensity score matching (PSM) analysis was performed. The postoperative outcomes, mortality, and length of hospital stay were compared between the surgery plus HIPEC and CRS alone groups.

Results: Propensity scoring generated 162 pairs. There was no statistically significant difference in the 30-day mortality rate between the groups (0% vs 0%, P = 1.000), and the morbidity rates were similar in both groups (7.4% vs 8.0%, P = 0.835). The surgery plus HIPEC group had a longer operative time (247.81 ± 64.70 vs 184.55 ± 29.56, P ≤ 0.001) and a slightly longer postoperative hospital stay (14.64 ± 5.24 vs 12.59 ± 3.76, P ≤ 0.001). No other baseline characteristics were significantly different.

Conclusions: Surgery plus HIPEC is feasible for select patients and is associated with prolonged surgery times and prolonged hospital stays, and there is no significant difference in mortality rates or postoperative outcomes.

References

Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S . Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003; 10(8):863-9. DOI: 10.1245/aso.2003.01.018. View

Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Baulieux J . Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88(2):358-63. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o. View

de Cuba E, Kwakman R, Knol D, Bonjer H, Meijer G, te Velde E . Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2012; 39(4):321-7. DOI: 10.1016/j.ctrv.2012.11.003. View

Cao C, Yan T, Black D, Morris D . A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009; 16(8):2152-65. DOI: 10.1245/s10434-009-0487-4. View

Franko J, Shi Q, Goldman C, Pockaj B, Nelson G, Goldberg R . Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2011; 30(3):263-7. PMC: 3269953. DOI: 10.1200/JCO.2011.37.1039. View

Glehen O, Mithieux F, Osinsky D, Beaujard A, Freyer G, Guertsch P . Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003; 21(5):799-806. DOI: 10.1200/JCO.2003.06.139. View

Sugarbaker P . Peritonectomy procedures. Ann Surg. 1995; 221(1):29-42. PMC: 1234492. DOI: 10.1097/00000658-199501000-00004. View

Glehen O, Mohamed F, Gilly F . Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004; 5(4):219-28. DOI: 10.1016/S1470-2045(04)01425-1. View

Goere D, Malka D, Tzanis D, Gava V, Boige V, Eveno C . Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?. Ann Surg. 2013; 257(6):1065-71. DOI: 10.1097/SLA.0b013e31827e9289. View

11.

Yan T, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36):6237-42. DOI: 10.1200/JCO.2009.23.9640. View

12.

Verwaal V, van Tinteren H, Ruth S, Zoetmulder F . Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004; 85(2):61-7. DOI: 10.1002/jso.20013. View

13.

Sugarbaker P . Surgical responsibilities in the management of peritoneal carcinomatosis. J Surg Oncol. 2010; 101(8):713-24. DOI: 10.1002/jso.21484. View

14.

Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzi S . Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014; 57(7):858-68. DOI: 10.1097/DCR.0000000000000149. View

15.

Spiliotis J, Rogdakis A, Vaxevanidou A, Datsis A, Zacharis G, Christopoulou A . Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. J BUON. 2009; 14(2):259-64. View

16.

Dindo D, Demartines N, Clavien P . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240(2):205-13. PMC: 1360123. DOI: 10.1097/01.sla.0000133083.54934.ae. View

17.

DAgostino Jr R . Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265-81. DOI: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b. View

18.

Lonjon G, Porcher R, Ergina P, Fouet M, Boutron I . Potential Pitfalls of Reporting and Bias in Observational Studies With Propensity Score Analysis Assessing a Surgical Procedure: A Methodological Systematic Review. Ann Surg. 2016; 265(5):901-909. DOI: 10.1097/SLA.0000000000001797. View

19.

Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M . Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008; 98(4):263-7. DOI: 10.1002/jso.21053. View

21.

Chua T, Yan T, Saxena A, Morris D . Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249(6):900-7. DOI: 10.1097/SLA.0b013e3181a45d86. View

22.

Jafari M, Halabi W, Stamos M, Nguyen V, Carmichael J, Mills S . Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2013; 149(2):170-5. DOI: 10.1001/jamasurg.2013.3640. View